Incorporation and washout of n-3 PUFA after high dose intravenous and oral supplementation in healthy volunteers

Clin Nutr. 2015 Jun;34(3):400-8. doi: 10.1016/j.clnu.2014.07.005. Epub 2014 Jul 15.

Abstract

Background & aims: Although the physiological effects of n-3 polyunsaturated fatty acids (n-3PUFA) are generally thought to require several weeks of exposure to allow their incorporation into plasma membranes, intravenous (IV) n-3PUFA attenuate the cardiovascular and neuroendocrine response to stress within 3 h. Whether oral n-3 PUFA exert similar early effects remains unknown.

Objective: To assess whether acute IV or short term oral n-3PUFA administration reproduces the metabolic effects of long term oral supplements during exercise, and how it relates to their incorporation into platelets and red blood cells (RBC) membranes.

Design: Prospective single center open label study in 8 healthy subjects receiving a 3-h infusion of 0.6 g/kg body weight n-3PUFA emulsion, followed one week later by an oral administration of 0.6 g/kg over 3 consecutive days. Maximal power output (cycling exercise), maximal heart rate (HR), blood lactate at exhaustion, and platelet function were measured at baseline and after IV or 3-day oral supplementation; platelet and RBC membrane composition were assessed until 15 days after n-3PUFA administration.

Results: Both IV and oral n-3PUFA significantly decreased maximal HR (-6% and -5%), maximal power output (-10%) and peak blood lactate (-47% and -52%) Platelet function tests were unchanged. The EPA and DHA membrane contents of RBC and platelets increased significantly, but only to 1.7-1.9% of fatty acid content.

Conclusion: The cardiovascular and metabolic effects of n-3 PUFA during exercise occur already within 1-3 days of exposure, and may be unrelated to changes in membranes composition. Effects occur within hours of administration and are unrelated to lipid membrane composition. Trial registered at clinicaltrials.gov as NCT00516178.

Keywords: Fish oil; Lactate; Membrane incorporation; Pharmacokinetic; Platelet function.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intravenous*
  • Administration, Oral*
  • Adult
  • Aged
  • Aged, 80 and over
  • Blood Platelets / drug effects
  • Blood Platelets / metabolism
  • Dietary Supplements*
  • Dose-Response Relationship, Drug
  • Erythrocyte Membrane / drug effects
  • Erythrocyte Membrane / metabolism
  • Fatty Acids / metabolism
  • Fatty Acids, Omega-3 / administration & dosage*
  • Fatty Acids, Omega-3 / pharmacokinetics
  • Female
  • Healthy Volunteers
  • Heart Rate / drug effects
  • Humans
  • Lactic Acid / blood
  • Male
  • Middle Aged
  • Pilot Projects
  • Prospective Studies
  • Triglycerides / blood

Substances

  • Fatty Acids
  • Fatty Acids, Omega-3
  • Triglycerides
  • Lactic Acid

Associated data

  • ClinicalTrials.gov/NCT00516178